We are rapidly approaching the end of the year. Time to review another eventful year in the history of anteris medical and its sister companies:
We are proudly looking back at a total of 5 EU & US approvals and a number of regulatory filings by our customers in the field of oncology and inflammatory diseases, to which our teams made significant contributions.
In addition, we were able to initiate a total of 8 new projects, ranging from the development of biosimilar combination products, prefilled syringes, autoinjectors, on-body injectors (OBIs) to an example of a very complex combination product falling into the category of an Advanced Therapy Medicinal Products (ATMP). Then, there are projects where anteris directly interacts with the FDA.
Continuing along the path to further develop our geographic reach, we managed to expand our portfolio now including the first customers in Asia.
Last but not least, we opened another legal entity in Switzerland, in particular to better serve and to be closer to our valued Swiss customers. The team is eagerly awaiting the beginning of January 2019 and can’t wait to spring into action with more than a dozen exciting projects to sink our teeth in.
Along those lines, a short glimpse into February 2019: We are looking forward to a Partnering Visit to South Korea (Seoul), supported by the German Federal Ministry for Economic Affairs and Energy. Our objective for this important event is to getting to know the Korean market and market players in more detail. We will establish contact with potential customers and try to support them in regulatory and product development, quality assurance and system questions, as well as the approval processes for European or US market entry.
We would like to thank all of our dear customers and partners for the trust they have placed in us, their collegiality and ambitious mandates for us, and wish them all a Merry Christmas and a Happy New Year!